Clearmind Medicine Gets Patent Approval for Proprietary Binge Behavior Regulator Program

MT Newswires Live08-22

Clearmind Medicine (CMND) shares were up 16% in recent after-hours activity Wednesday after the company said it received a new patent approval from the US Patent and Trademark Office for its proprietary binge behavior regulator program.

The patent covers Clearmind's innovative psychedelic molecule 5-methoxy-2-aminoindan, among other things, according to the company.

The latest patent expands the company's intellectual property portfolio to 29 patents across 19 patent families, Clearmind added.

Price: 1.5200, Change: +0.22, Percent Change: +16.92

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment